Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Johnson & Johnson (JNJ) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Johnson & JohnsonTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs Vir Biotechnology Inc. Common Stock — how do they compare? Johnson & Johnson trades at $255.28 (market cap $599.12B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Johnson & Johnson is far larger — about 332.8× Vir Biotechnology Inc. Common Stock's market cap, and Johnson & Johnson pays a 2.16% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

JNJVIR
Market Cap
$599.12B$1.80B
Volume
16,640,9511,782,836
Sector
HealthHealth
52-Week High
$278.43$11.78
52-Week Low
$186.00$5.12
Typical Hold Time
129 Days0 Days
Enterprise Value
$627.40B$1.36B
Dividend Yield
2.16%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson & Johnson

JNJ trades at $253.91, down 3.72% on the day, amid a mixed technical and fundamental backdrop. The stock shows strong profitability with a 21.48% net income margin and 25.74% ROE, supported by three consecutive quarterly EPS beats. Analyst consensus is bullish with a $282.73 price target, though recent news highlights competitive pressures and patent cliff concerns. Cash flow trends indicate robust operations but elevated investing outflows.

The outlook remains positive given JNJ's diversified healthcare portfolio and innovation pipeline, but investors face risks from debt levels rising to 24.06% of assets and biosimilar competition. Near-term resistance lies at $265, with support at $257. Institutional sentiment favors growth in pharmaceuticals and medical technology, though macroeconomic and regulatory headwinds persist.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JNJ
84% Buy16% Sell
Avg holding period · 129 Days
VIR
51% Buy49% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →